OXiGENE (OXGN) Announces Publication of Final FACT Study Data in Journal Thyroid Suggest Survival Benefit of ZYBRESTAT® in Patients With Anaplastic Thyroid Cancer
6/10/2013 9:17:50 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SOUTH SAN FRANCISCO, Calif., June 10, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer, announced the publication in the peer-reviewed journal Thyroid of the final results of a randomized controlled global trial in anaplastic thyroid cancer (ATC) which suggests a survival benefit in patients who received ZYBRESTAT and chemotherapy versus chemotherapy alone.
Help employers find you! Check out all the jobs and post your resume.
comments powered by